140 related articles for article (PubMed ID: 34838271)
1. Lifetime Health and Economic Outcomes of Active Surveillance, Radical Prostatectomy, and Radiotherapy for Favorable-Risk Localized Prostate Cancer.
Degeling K; Corcoran NM; Pereira-Salgado A; Hamid AA; Siva S; IJzerman MJ
Value Health; 2021 Dec; 24(12):1737-1745. PubMed ID: 34838271
[TBL] [Abstract][Full Text] [Related]
2. Radical prostatectomy versus deferred treatment for localised prostate cancer.
Vernooij RW; Lancee M; Cleves A; Dahm P; Bangma CH; Aben KK
Cochrane Database Syst Rev; 2020 Jun; 6(6):CD006590. PubMed ID: 32495338
[TBL] [Abstract][Full Text] [Related]
3. Focal therapy versus radical prostatectomy and external beam radiotherapy as primary treatment options for non-metastatic prostate cancer: results of a cost-effectiveness analysis.
Reddy D; van Son M; Peters M; Bertoncelli Tanaka M; Dudderidge T; Cullen E; Ho CLT; Hindley RG; Emara A; McCracken S; Orczyk C; Shergill I; Mangar S; Nigam R; Virdi J; Moore CM; Arya M; Shah TT; Winkler M; Emberton M; Falconer A; Belsey J; Ahmed HU
J Med Econ; 2023; 26(1):1099-1107. PubMed ID: 37656223
[TBL] [Abstract][Full Text] [Related]
4. The cost-utility of open prostatectomy compared with active surveillance in early localised prostate cancer.
Koerber F; Waidelich R; Stollenwerk B; Rogowski W
BMC Health Serv Res; 2014 Apr; 14():163. PubMed ID: 24721557
[TBL] [Abstract][Full Text] [Related]
5. The impact of life expectancy on cost-effectiveness of treatment options for clinically localized prostate cancer.
Naser-Tavakolian A; Venkataramana A; Spiegel B; Almario C; Kokorowski P; Freedland SJ; Anger JT; Leppert JT; Daskivich TJ
Urol Oncol; 2023 Apr; 41(4):205.e1-205.e10. PubMed ID: 36737259
[TBL] [Abstract][Full Text] [Related]
6. Modelling the lifetime cost-effectiveness of radical prostatectomy, radiotherapy and active monitoring for men with clinically localised prostate cancer from median 10-year outcomes in the ProtecT randomised trial.
Sanghera S; Mohiuddin S; Coast J; Garfield K; Noble S; Metcalfe C; Lane JA; Turner EL; Neal D; Hamdy FC; Martin RM; Donovan JL;
BMC Cancer; 2020 Oct; 20(1):971. PubMed ID: 33028256
[TBL] [Abstract][Full Text] [Related]
7. Sexual function with localized prostate cancer: active surveillance vs radical therapy.
van den Bergh RC; Korfage IJ; Roobol MJ; Bangma CH; de Koning HJ; Steyerberg EW; Essink-Bot ML
BJU Int; 2012 Oct; 110(7):1032-9. PubMed ID: 22260273
[TBL] [Abstract][Full Text] [Related]
8. Cost-Effectiveness of Active Surveillance, Radical Prostatectomy and External Beam Radiotherapy for Localized Prostate Cancer: An Analysis of the ProtecT Trial.
Sharma V; Wymer KM; Borah BJ; Barocas DA; Thompson RH; Karnes RJ; Boorjian SA
J Urol; 2019 Nov; 202(5):964-972. PubMed ID: 31112105
[TBL] [Abstract][Full Text] [Related]
9. Economic evaluation of treatments for patients with localized prostate cancer in Europe: a systematic review.
Becerra V; Ávila M; Jimenez J; Cortes-Sanabria L; Pardo Y; Garin O; Pont A; Alonso J; Cots F; Ferrer M;
BMC Health Serv Res; 2016 Oct; 16(1):541. PubMed ID: 27716267
[TBL] [Abstract][Full Text] [Related]
10. Primary treatments for clinically localised prostate cancer: a comprehensive lifetime cost-utility analysis.
Cooperberg MR; Ramakrishna NR; Duff SB; Hughes KE; Sadownik S; Smith JA; Tewari AK
BJU Int; 2013 Mar; 111(3):437-50. PubMed ID: 23279038
[TBL] [Abstract][Full Text] [Related]
11. Health-related quality of life in active surveillance and radical prostatectomy for low-risk prostate cancer: a prospective observational study (HAROW - Hormonal therapy, Active Surveillance, Radiation, Operation, Watchful Waiting).
Ansmann L; Winter N; Ernstmann N; Heidenreich A; Weissbach L; Herden J
BJU Int; 2018 Sep; 122(3):401-410. PubMed ID: 29603553
[TBL] [Abstract][Full Text] [Related]
12. Management Strategies and Patient Selection After a Hospital Funding Reform for Prostate Cancer Surgery in Canada.
Wettstein MS; Palmer KS; Kulkarni GS; Paterson JM; Ling V; Lapointe-Shaw L; Li AH; Brown A; Taljaard M; Ivers N
JAMA Netw Open; 2019 Aug; 2(8):e1910505. PubMed ID: 31469400
[TBL] [Abstract][Full Text] [Related]
13. Cost effectiveness of risk-prediction tools in selecting patients for immediate post-prostatectomy treatment.
Zubek VB; Konski A
Mol Diagn Ther; 2009; 13(1):31-47. PubMed ID: 19351214
[TBL] [Abstract][Full Text] [Related]
14. Active Surveillance Versus Radical Prostatectomy in Favorable-risk Localized Prostate Cancer.
Thomsen FB; Røder MA; Jakobsen H; Langkilde NC; Borre M; Jakobsen EB; Frey A; Lund L; Lunden D; Dahl C; Brasso K
Clin Genitourin Cancer; 2019 Aug; 17(4):e814-e821. PubMed ID: 31196798
[TBL] [Abstract][Full Text] [Related]
15. The cost-effectiveness of active surveillance compared to watchful waiting and radical prostatectomy for low risk localised prostate cancer.
Lao C; Edlin R; Rouse P; Brown C; Holmes M; Gilling P; Lawrenson R
BMC Cancer; 2017 Aug; 17(1):529. PubMed ID: 28789623
[TBL] [Abstract][Full Text] [Related]
16. Cost-Effectiveness of Primary Radiation Therapy Versus Radical Prostatectomy for Intermediate- to High-Risk Prostate Cancer.
Dorth JA; Lee WR; Chino J; Abouassaly R; Ellis RJ; Myers ER
Int J Radiat Oncol Biol Phys; 2018 Feb; 100(2):383-390. PubMed ID: 29353655
[TBL] [Abstract][Full Text] [Related]
17. A decision support model for cost-effectiveness of radical prostatectomy in localized prostate cancer.
Lyth J; Andersson SO; Andrén O; Johansson JE; Carlsson P; Shahsavar N
Scand J Urol Nephrol; 2012 Feb; 46(1):19-25. PubMed ID: 21905981
[TBL] [Abstract][Full Text] [Related]
18. Association Between Radiation Therapy, Surgery, or Observation for Localized Prostate Cancer and Patient-Reported Outcomes After 3 Years.
Barocas DA; Alvarez J; Resnick MJ; Koyama T; Hoffman KE; Tyson MD; Conwill R; McCollum D; Cooperberg MR; Goodman M; Greenfield S; Hamilton AS; Hashibe M; Kaplan SH; Paddock LE; Stroup AM; Wu XC; Penson DF
JAMA; 2017 Mar; 317(11):1126-1140. PubMed ID: 28324093
[TBL] [Abstract][Full Text] [Related]
19. Radiotherapy after radical prostatectomy: Effect of timing of postprostatectomy radiation on functional outcomes.
Huelster HL; Laviana AA; Joyce DD; Huang LC; Zhao Z; Koyama T; Hoffman KE; Conwill R; Goodman M; Hamilton AS; Wu XC; Paddock LE; Stroup A; Cooperberg M; Hashibe M; O'Neil BB; Kaplan SH; Greenfield S; Penson DF; Barocas DA
Urol Oncol; 2020 Dec; 38(12):930.e23-930.e32. PubMed ID: 32736934
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
